Biologic effects and safety of stavudine: overview of phase I and II clinical trials.
Biologic effects and safety of stavudine: overview of phase I and II clinical trials.
复制标题
司他夫定的生物效应和安全性：I 期和 II 期临床试验概述。
DOI：
10.1093/infdis/171.supplement_2.s113
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
Skowron,G
中科院分区：
文献类型：
--
作者：
Skowron,G
Data on the biologic effects and safety of stavudine in patients with AIDS and AIDS-related complex represent results of two phase I trials(n= 84), another phase I study of patients with hematologic intolerance to zidovudine(n= 23), and a phase II trial(n= 152). The daily doses of stavudine ranged from 0.1 to 12.0 rug/kg. Increases in CD4 cell count, declines in serum p24 antigen, and weight gain were all related to the dose of stavudine. Doses of <2 rug/kg/day(n =216) were well-tolerated, with a median duration of therapy of > 48 weeks in the phase I studies and >79 weeks in the phase II study. The predominant dose-limiting toxicity was peripheral neuropathy, which was related to both the dose and duration oftreatment with stavudine. Elevations ofliver enzymes were seen in some patients but appeared to be related to underlying disease rather than treatment. There was no evidence of dose-related hematologic toxicity.
登录
查看更多内容
司他夫定在人类免疫缺陷病毒感染患者中的剂量相关活性。
影响因子：
6.4
作者：
Eskild A. Petersen;C. H. Ramírez;W. Hardy;Robert Schwartz;Henry S. Sacks;Stephen E. Follansbee;Dolores M. Peterson;Anne H. Cross;Robert E. Anderson;Lisa M. Dunkle
通讯作者：
Lisa M. Dunkle
人类免疫缺陷病毒 (HIV) 感染中循环 p24 抗原水平和对双脱氧胞苷的反应。
影响因子：
39.2
作者：
T. Merigan;G. Skowron;S. Bozzette;Richman Dd;R. Uttamchandani;M. Fischl;R. Schooley;M. Hirsch;W. Soo;C. Pettinelli;Herbert H. Schaumburg
通讯作者：
Herbert H. Schaumburg
司他夫定治疗艾滋病和艾滋病相关综合症患者：艾滋病临床试验组 089。
DOI：
10.1093/infdis/171.supplement_2.s123
发表时间：
1995
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Murray,HW;Squires,KE;Weiss,W;Sledz,S;Sacks,HS;Hassett,J;Cross,A;Anderson,RE;Dunkle,LM
通讯作者：
Dunkle,LM
2,3-双脱氧肌苷 (ddI) 用于患有获得性免疫缺陷综合征或艾滋病相关综合症的患者。
DOI：
10.1056/nejm199005103221901
发表时间：
1990
期刊：
The New England journal of medicine
影响因子：
--
作者：
Lambert,JS;Seidlin,M;Reichman,RC;Plank,CS;Laverty,M;Morse,GD;Knupp,C;McLaren,C;Pettinelli,C;Valentine,FT
通讯作者：
Valentine,FT
患有获得性免疫缺陷综合征或艾滋病相关综合症的患者每天服用一次 2,3-双脱氧肌苷 (ddI)。
DOI：
10.1056/nejm199005103221902
发表时间：
1990
期刊：
The New England journal of medicine
影响因子：
--
作者：
T. Cooley;L. Kunches;C. Saunders;Jitka K. Ritter;C. J. Perkins;C. Mclaren;R. Mccaffrey;H. Liebman
通讯作者：
H. Liebman